<DOC>
	<DOCNO>NCT01804829</DOCNO>
	<brief_summary>The purpose study test safety efficacy Civacir® prevent recurrence Hepatitis C Virus ( HCV ) liver transplant .</brief_summary>
	<brief_title>Civacir® Polyclonal Immune Globulin ( IgG ) Prevent Hepatitis C Virus ( HCV ) Recurrence Liver Transplant Patients .</brief_title>
	<detailed_description>Civacir® 10 % , Hepatitis C Immune Globulin Intravenous ( Human ) high-titer human polyclonal immune globulin ( IgG ) contain diversity antibody target bind hepatitis C virus ( HCV ) prevent infection . Subjects reduce viral load le 100 IU/ml HCV RNA 24 week antiviral therapy prior liver transplant enrol study . There requirement reach undetectable virus prior transplant function Civacir® neutralize remain virus circulation . Subjects randomize Civacir® treatment arm receive study drug infusion start day liver transplant follow 15 dos 10 week period prevent recurrence quantifiable Hepatitis C Virus ( HCV ) liver transplant . The study evaluate dosing arm range 200 mg/kg 300 mg/kg compare control arm . For primary endpoint , efficacy define persistent viral load suppression maintain HCV RNA level low limit quantitation determine central laboratory Polymerase Chain Reaction ( PCR ) 22 week post-liver transplant 34 week post-liver transplant demonstrate durability effect .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hepatitis , Viral , Human</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Written inform consent obtain prior studyspecific assessment within 3 month ( reconsent ) orthotopic liver transplantation ( OLT ) . HCV Genotype 1 6 Infection . Subjects begin new antiviral therapy regimen ( regardless prior treatment failure ) include 24 week prior day OLT . Most recent evidence within last 4 week HCV RNA &lt; 100 IU/mL . Subjects may randomize base local lab HCV RNA . Male female subject ( age 1880 year ) . Subject weight 250 pound . Stable patient condition opinion investigator would permit safe participation study . Retransplantation due viral recurrence . Positive HIV HBV test within 90 day prior transplantation . Most recent PCR test indicate HCV RNA ≥100 IU/mL within 4 week OLT . Subjects received organ HCV positive donor . Serum creatinine level &gt; 2.5 time upper limit normal advanced renal disease screening . Pregnancy single contraceptive measure lactation period ( female ) . Known intolerance immunoglobulin comparable substance ( e.g . vaccination reaction ) . Known absolute Immunoglobulin A ( IgA ) deficiency . Known intolerance protein human origin . Participation another clinical trial within 90 day sign Informed Consent Form ( ICF ) study ( observational/ noninterventional 988 study allow ) , and/or previous participation 988 study ( except Study 988 screen failure ) . Active drug and/or alcohol abuse . Inability lack motivation participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HCV Liver Transplant Immunoglobulin PCR SVR</keyword>
</DOC>